Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence
What is the purpose of this trial?
The purpose of this study is to develop ways to examine how HIV stays in your body after someone starts medication assisted therapy (MAT) (e.g. buprenorphine/naloxone, buprenorphine, methadone or extended-release naltrexone), for the treatment of opioid use disorder, and to see how different types of MAT changes how HIV in the body.
The researchers will follow all participants and schedule regular interviews and blood draws to gather information. This will enable them to look at the presence of specific factors associated with HIV and treatment for opioid use disorder over time. The study will last for 3 months.
- Ages18 years and older
- Trial withNational Institute on Drug Abuse (NIDA)
- Start Date10/22/2018
- End Date04/30/2023
- Last Updated07/15/2021
- Study HIC#2000023013